Company Insights

EVR customer relationships

Explore interactive graphBrowse insights index

EVR customers relationship map

Evercore Partners (EVR): Client Relationships That Drive Advisory Economics

Thesis — Evercore monetizes advice. The firm operates a fee-for-service investment banking and investment management model: high-margin advisory fees from M&A, restructurings and capital markets mandates, supplemented by fee‑based wealth and asset management tied to AUM. Advisory engagements are mostly short‑term, deal‑by‑deal mandates (spot and placement fees) with recurring subscription-style revenue from published research and fee‑percent AUM in wealth management. For investor due diligence on EVR, the client roster below illustrates the firm’s mix of large-cap corporate mandates, sponsor/private capital work and repeat special‑committee engagements — the primary sources of advisory fee pools. For a broad view of Evercore’s business, visit https://nullexposure.com/.

How the operating model shows up in real mandates

Evercore’s relationships map directly to the constraints in its filings. Contracts skew short and transactional (underwriting and M&A fees recognized at completion), with subscription and AUM‑linked components in research and wealth management. The client base is global but U.S.‑heavy, with meaningful EMEA and APAC activity supporting cross‑border mandates. No single client accounts for more than 10% of revenue, indicating low single‑client concentration but high dependence on the Investment Banking & Equities segment for revenue and fee generation. Evercore acts primarily as a service provider — active, often exclusive or lead adviser — on high‑criticality mandates (special committees, large M&A and structured sales), consistent with its positioning as a boutique advisory specialist.

  • Contract posture: predominantly short-term, deal-based fees with pockets of subscription and usage/AUM-based recurring income.
  • Counterparties: a mix of very large enterprises, financial sponsors, and high‑net‑worth individuals and endowments through EWM.
  • Geography: North America dominant, meaningful EMEA footprint and smaller APAC revenues.
  • Materiality: individual client engagements are typically immaterial to consolidated revenues, but advisory fees are collectively critical to firm profitability.

If you want a concise feed of Evercore’s deal activity and client references, see https://nullexposure.com/.

What the relationship list shows about client strategy

Below I catalog Evercore’s reported client engagements from public news and press releases. Each entry is a plain-English note of the mandate and its source. This list covers the full set of relationships referenced in the gathered results.

  • ZD — Evercore and Citi served as financial advisors to Ziff Davis on the sale of its connectivity division to Accenture. Source: Pulse2 report (Mar 10, 2026).
  • GCMG — Evercore acted as structuring and placement agent for a $625 million structured solution for Grosvenor; this was reported via GlobeNewswire/TMT newswire (Feb–Mar 2026).
  • AVIR — Atea engaged Evercore to explore strategic partnerships around its Phase 3 HCV program, according to Fierce Biotech (FY2025 disclosure reported Mar 2026).
  • NLY — Evercore served as financial advisor to Annaly Capital Management in the portfolio/platform sale to Slate Asset Management, per a PR Newswire release (FY2021 disclosure surfaced Mar 2026).
  • CMTG — Evercore acted as lead financial advisor on Claros Mortgage Trust’s $500M secured term loan refinancing; multiple market outlets and StockTitan referenced this (Mar 2026).
  • AURA — Evercore ISI and Leerink Partners acted as joint bookrunning managers for Aura Biosciences’ proposed offering, per GlobeNewswire (May 2025).
  • OSUR — Evercore is serving as financial advisor to OraSure Technologies (including strategic communications and legal advisors) through multiple statements and GlobeNewswire press releases (FY2025–FY2026).
  • NUVB‑WS — Evercore acted as exclusive financial advisor to Nuvation Bio on the acquisition of AnHeart Therapeutics, per a Trading/Market release (FY2024 closure referenced Mar 2026).
  • IMA — Evercore served as exclusive financial advisor to Inmagene in its merger with Ikena Oncology and concurrent private placement, per GlobeNewswire (FY2024–FY2025).
  • SATS — Evercore served as exclusive financial advisor to the EchoStar special committee on the merger with DISH, with Cravath as legal counsel; reported via corporate press (FY2024 filings reflected Jan 2024 announcement).
  • GEMI — Evercore ISI acted as a bookrunner for Gemini’s planned IPO alongside other banks, per CoinDesk and follow‑up filings (FY2025).
  • TRAK — Evercore acted as financial advisor to Dealertrack in the Dealertrack sale/acquisition activity, reported in industry press (FY2015 historical reference).
  • CRGY — Evercore served as a financial advisor to Crescent Energy in its acquisition of Vital Energy, per Euro-Petrole report (FY2025).
  • SABR — Evercore advised Sabre on the sale of its Hospitality Solutions business unit to TPG, with legal counsel noted in the PR release (FY2025).
  • Danaher (DHR) — Evercore’s advisory work on Danaher attracted market attention and an intra‑day stock move during Q1 2026 coverage, per SahmCapital commentary (Apr–May 2026).
  • ASBA / ASB‑P‑E — Evercore advised Associated Banc‑related transactions and was cited as financial advisor with Wachtell as legal counsel in Yahoo Finance reporting (FY2025).
  • TEVA — Evercore served as financial advisor to Teva in its acquisition of Emalex Biosciences, according to GlobeNewswire and Yahoo Finance (FY2026).
  • PGEN — Evercore acted as financial advisor to Precigen for a non‑dilutive financing, with Davis Polk as legal counsel; InvestingNews covered the transaction (FY2025).
  • GLOP‑P‑B / GLOP‑P‑A — Evercore advised the Conflicts Committee in GasLog and GasLog Partners transactions, per historical Globe and Cyprus Shipping News coverage (FY2019–FY2023).
  • QVCC — Evercore was reported as financial advisor to QVC Group amid debt restructuring discussions, according to Debtwire coverage cited by IonAnalytics (FY2025).
  • SEE — Sealed Air supplemented a proxy with Evercore valuation analysis showing implied equity value ranges relative to a proposed $42.15 merger price, per TradingView summary (FY2026).
  • INGN — Evercore was serving as financial advisor to Inogen, per CityBiz news (FY2026).
  • CTOR — The Citius Oncology commercialization news mentions other vendors; Evercore-related context is limited in the cited article (Marketscreener, FY2025).
  • MAPS — The special committee for Weedmaps retained Evercore as independent financial advisor with Allen & Overy as legal counsel, per FinancialContent and MG Magazine (FY2025).
  • PTRN — Evercore ISI acted as a joint bookrunning manager on Pattern’s IPO, per Thailand Business News (FY2025).
  • PFAI — In historical M&A coverage, Evercore advised Pinnacle Foods in the Conagra transaction, per Globe and Mail archive (FY2018).
  • DVN — Devon supplemented proxy materials with Evercore‑provided valuation ranges in connection with its merger vote disclosures, as reported by TradingView (FY2026).
  • BHC — Evercore acted as financial advisor for Bausch Health Companies in an exchange offer, according to TradingView reporting (FY2025).
  • RLYB — Evercore served as lead financial advisor to Rallybio in its merger with Candid Therapeutics, per CityBiz (FY2026).
  • CPLP — Evercore served as financial advisor to Capital Product Partners’ committee on an acquisition, per VesselFinder press (FY2021 disclosure cited).
  • NE — Evercore acted as financial adviser in Noble Corporation’s Chapter 11 restructuring and emergence, with Skadden and AlixPartners involved (Financier Worldwide, FY2020–FY2021).
  • MDLN — Evercore ISI was among bookrunners for Medline’s secondary offering, per GlobeNewswire market release (FY2026).
  • MLAB — Evercore acted as bookrunner on Mesa Laboratories’ public offerings, per GlobeNewswire historical release (FY2019).
  • FDMT — Evercore ISI was joint bookrunning manager for 4DMT’s offering, per GlobeNewswire (FY2025).
  • GRNT‑WS — BofA and Evercore Group L.L.C. acted as representatives of underwriters in a 424B3 filing, per SEC prospectus (FY2023).
  • CL M / ELYM — SVB Leerink, Evercore ISI and others served as underwriters on Eliem Therapeutics’ IPO, per MarketBeat (FY2021; coverage cited 2025–2026 commentary).
  • SABR (historical) — Evercore appeared as a co‑manager in Sabre’s IPO pricing historical report, per SouthLakeStyle archive (FY2014).
  • HBAN — Evercore advised Huntington Bancshares on the $1.9 billion acquisition of Veritex Holdings, as noted in earnings call transcripts and coverage (FY2025).
  • BDX (Becton Dickinson) — Evercore advised Becton Dickinson on the $17.5 billion Reverse Morris Trust combining Biosciences and Diagnostic Solutions with Waters, per earnings call transcript coverage (FY2025).
  • CHTR / Cox Communications — Evercore advised on Cox‑Charter merger activity and valuations cited in investor calls and transcripts (FY2025).
  • Foot Locker / DKS — Evercore advised on the sale of Foot Locker to Dick’s Sporting Goods for $2.5 billion, per earnings call summaries (FY2025).
  • CCC — Evercore Group acted as financial adviser to CCC in a prior engagement, per Insurance Journal (FY2021).
  • GEMI (bookrunning) — Evercore ISI and others were named as bookrunners in Gemini’s SEC registration/IPO filings (LeapRate and CoinDesk coverage, FY2025).
  • RRGB — Evercore Group L.L.C. served as sales agent for Red Robin ATM offering filings, per corporate IR release (FY2025).
  • ZIM — ZIM’s board engaged Evercore as financial adviser in competing buyout proposals and structured sale processes, reported by Tech/Calcalist and other outlets (FY2025).
  • OR more minor or legacy mandates referenced across filings and press releases — Evercore also shows up as adviser, bookrunner or conflicts‑committee counsel on a wide range of client matters (examples include Mesa, Pattern, FlowCo offerings and other sector deals reported between FY2014–FY2026 in public releases and market reporting).

Investment implications and risk signals

  • Revenue concentration on advisory economics is high. The firm’s Investment Banking & Equities segment generated ~97% of revenues in 2024 before Other Revenue, underscoring reliance on deal activity for near‑term earnings (company filings).
  • Deal timing risk is intrinsic. Short-term/spot recognition of underwriting and advisory fees produces revenue volatility tied to market windows and deal cycles.
  • Diversifiers exist. Wealth management subscription/AUM fees and recurring research subscriptions provide a partial cushion, but they are smaller relative to advisory income.
  • Low client concentration reduces single-client counterparty risk, but Evercore’s economics depend on continued access to large, complex mandates and special‑committee work — areas where reputation and execution capacity are critical.

Bottom line

Evercore’s public relationship trail confirms its role as a go‑to adviser on large, high‑stakes transactions across sectors and geographies. The evidence set reinforces the firm’s advisory‑led, fee‑for‑service economics: transactional upside with inherent volatility, supplemented by smaller recurring revenue streams. For further, continually updated deal flow tracking and client analytics, visit https://nullexposure.com/.

Key takeaway: Evercore’s client list is deep, deal‑centric and globally distributed — precisely the profile investors should expect for a boutique advisory franchise whose earnings track M&A and capital‑markets cycles.

Join our Discord